PT - JOURNAL ARTICLE AU - Ismail, Zahinoor AU - Guan, Dylan AU - Vellone, Daniella AU - Ballard, Clive AU - Creese, Byron AU - Corbett, Anne AU - Pickering, Ellie AU - Bloomfield, Adam AU - Hampshire, Adam AU - Sekhon, Ramnik AU - Roach, Pamela AU - Smith, Eric E. TI - The Canadian platform for research online to investigate health, quality of life, cognition, behaviour, function, and caregiving in aging (CAN-PROTECT): study protocol, platform description, and preliminary analyses AID - 10.1101/2023.12.16.23300094 DP - 2023 Jan 01 TA - medRxiv PG - 2023.12.16.23300094 4099 - http://medrxiv.org/content/early/2023/12/17/2023.12.16.23300094.short 4100 - http://medrxiv.org/content/early/2023/12/17/2023.12.16.23300094.full AB - Background Preventing or reducing the risk of cognitive decline and dementia is of great public health interest. Longitudinal data from diverse samples are needed to properly inform clinicians, researchers, and policy makers. CAN-PROTECT is a recently launched online observational cohort study that assesses factors contributing to both risk for incident cognitive decline and dementia and resilience against brain aging, in participants across the lifespan.Methods Measures of cognition, behaviour, and quality of life administered to both participants and study partners were compared using partial Spearman correlations adjusted for participant and study partner age, sex, and education. In participants, relationships between cognition, behaviour, function, and quality of life were examined using adjusted multivariable linear and negative binomial regression models.Results In the first three-month window, 2150 participants spanning all Canadian provinces enrolled; 637 nominated study partners had already completed assessments. Engagement with the study was excellent, with many optional assessments completed. Initial analyses demonstrated relationships between cognition, behaviour, function, and quality of life.Discussion These preliminary results speak to the utility and feasibility of CAN-PROTECT to obtain data relevant to brain health, highlighting the public interest in participating in studies on cognition. The online portal facilitated participation of a geographically diverse sample. This group is ideal to study brain aging, dementia prevention, and early detection of neurodegenerative disease. Longitudinal data will provide additional insights. Several features of CAN-PROTECT are important to consider in terms of assessing risk and resilience in Canadians, and for further development and recruitment of a research-ready cohort.HIGHLIGHTSCAN-PROTECT is a longitudinal online study of risk and resilience to brain agingNeuropsychological testing and health– and aging-related outcomes are obtainedData presented are from the first 2150 participants, mean age 62.9 (77.6% female)Associations between cognition, behaviour, function, and quality of life were foundCAN-PROTECT is a feasible platform to obtain participant and study partner dataCompeting Interest StatementThe authors have declared no competing interest.Funding StatementCAN-PROTECT was supported by Gordie Howe CARES. The funder did not influence study design, collection, analysis, interpretation, writing, or decision to submit for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Conjoint Health Research Ethics Board at the University of Calgary Ethics provided approval for CAN-PROTECT (REB21-1065).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors